MBX Biosciences (MBX) Operating Expenses (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Operating Expenses data on file, last reported at $27.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 2.77% year-over-year to $27.3 million; the trailing twelve-month figure through Mar 2026 stood at $78.7 million (up 63.92% YoY), and the FY2025 full-year result was $98.1 million, up 43.79% from the prior year.
• Operating Expenses advanced to $27.3 million in Q1 2026, from $25.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $27.3 million in Q1 2026 to a low of $1.3 million in Q1 2024.
• A 4-year average of $13.5 million and a median of $10.9 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses sank 87.25% in 2024 and jumped 1959.7% in 2025, its largest moves.
• Tracing MBX's Operating Expenses over 4 years: stood at $10.0 million in 2023, then surged by 86.27% to $18.6 million in 2024, then surged by 38.61% to $25.8 million in 2025, then increased by 5.7% to $27.3 million in 2026.
• Business Quant data shows MBX's Operating Expenses at $27.3 million in Q1 2026, $25.8 million in Q4 2025, and $23.9 million in Q3 2025.